In this week's episode of "The Top Line," we're looking at two companies building on recent successes and pursuing new ...
Some six years after scoring an initial FDA nod in neuromyelitis optica spectrum disorder, Roche’s IL-6 receptor agonist ...
Roche extended its China shopping spree with a $1 billion-plus obesity deal. | Roche extended its China shopping spree with a ...
U.S.-based generic drugmaker Par Health has issued a voluntary recall of 22 lots of the direct thrombin inhibitor argatroban ...
In the fiercely competitive inflammatory bowel disease (IBD) market, Eli Lilly is making the case for its antibody Omvoh as a ...
Meridian Medical Technologies—the global health security subsidiary of CDMO Kindeva—just secured a major contract, worth up to a potential $226 million, with the DoD's Defense Logistics Agency to ...
Following a bumpy regulatory road that involved a refusal-to-file, ImmunityBio has won FDA approval to expand Anktiva into ...
Hot off a pair of key FDA green lights this summer, rare disease specialist Ultragenyx has wasted little time cashing in a ...
As the momentum continues to pick up at NorthStar Medical Technologies, the radioisotope producer is strengthening ties in ...
Sanofi has avoided a European Union fine after antitrust regulators accepted its commitments to address the alleged ...
With a yearslong patent dispute between the two drugmakers finally put to bed—complete with a hefty settlement payout—United ...
Since the drug’s approval and launch earlier this year, J&J has recorded more than 20,000 patient starts on Icotyde, funneled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results